HypoPet was founded as a spin-off company from the University Zurich in 2013 and is now based in Zurich (Switzerland) and Eschen (Liechtenstein). Today the company HypoPet is the result of a merger of HypoPet AG and Saiba Animal Health GmbH which took place to secure exclusive use of Saiba’s Virus-like nanoparticle platform for use in companion animal health.
HypoPet is establishing a broad and innovative animal health drug pipeline targeting major unmet medical needs in veterinary medicine.
HypoPet is looking to raise capital to fund ongoing and new R & D activities and form strategic alliances with top-tier companies to advance its pipeline projects and maximize the potential of its platform technology.
We are happy to answer your questions regarding our corporate development and provide financial Information.
We kindly ask you to contact us:
Dr. Gary Jennings